z-logo
Premium
Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte–colony‐stimulating factor by single‐dose administration of AMD3100, a CXCR4 antagonist
Author(s) -
Liles W. Conrad,
Rodger Elin,
Broxmeyer Hal E.,
Dehner Christine,
Badel Karin,
Calandra Gary,
Christensen Jeff,
Wood Brent,
Price Thomas H.,
Dale David C.
Publication year - 2005
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/j.1537-2995.2005.04222.x
Subject(s) - leukapheresis , granulocyte colony stimulating factor , cd34 , haematopoiesis , plerixafor , granulocyte , progenitor cell , medicine , immunology , transplantation , cxcr4 , andrology , stem cell , biology , chemotherapy , microbiology and biotechnology , chemokine , immune system
BACKGROUND: AMD3100, a selective antagonist of CXCR4, rapidly mobilizes CD34+ hematopoietic progenitor cells (HPCs) from marrow to peripheral blood with minimal side effects. STUDY DESIGN AND METHODS: To further investigate potential clinical utility of AMD3100 for CD34+ cell mobilization and collection, a Phase I study in normal volunteers was performed examining single‐dose administration of AMD3100 alone and in combination with a standard 5‐day granulocyte–colony‐stimulating factor (G–CSF) regimen. RESULTS: AMD3100 (160 µg/kg × 1 on Day 5) significantly increased both G–CSF‐stimulated (10 µg/kg/day) mobilization of CD34+ cells (3.8‐fold) and leukapheresis yield of CD34+ cells. Moreover, collection of CD34+ cells was comparable between individuals mobilized by a single‐dose regimen of AMD3100 (240 µg/kg) and individuals mobilized with a 5‐day regimen of G–CSF. AMD3100‐mobilized leukapheresis products contained significantly greater numbers of T and B cells compared to G–CSF‐stimulated leukapheresis products. CONCLUSION: These findings indicate that AMD3100 can be used alone or as an adjunct to G–CSF to mobilize cells for HPC transplantation.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here